HAEMATO AG |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.4 EUR | -0.57% |
|
-4.92% | 0.00% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.26 times its sales.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| 0.00% | 98.31M | - | ||
| +18.88% | 80.5B | A | ||
| +14.11% | 9.15B | A- | ||
| -14.14% | 4.9B | A- | ||
| +43.39% | 4.49B | - | ||
| +18.90% | 4.44B | B- | ||
| +7.93% | 2.19B | B | ||
| -28.40% | 2.13B | C- | ||
| +15.93% | 2.1B | - | - | |
| -43.17% | 1.78B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- HAEK Stock
- Ratings HAEMATO AG
